Clinical trials: Chronic Hep B
Liver Fibrosis, Liver Cirrhosis
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness
Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease.
- Conditions
- Liver Fibrosis, Liver Cirrhosis, NAFLD (Nonalcoholic Fatty Liver Disease), HEPATITIS B CHRONIC
- Trial name
- NCT07716384
- Testing
- Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan)
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepatitis B, Chronic, Hepatitis D
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection.
- Trial name
- NCT04847440
- Testing
- ATI-2173, Viread, AB-729
- Where
- 2 sites in Moldova, Ukraine
- Volunteers
- 40 people
- Sponsor
- Antios Therapeutics, Inc
Chronic Hepatitis B
NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients
The general objective of the present clinical trial is to compare the therapeutic efficacy of a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) [later called…
- Trial name
- NASVAC (NCT01374308)
- Testing
- NASVAC, Pegylated interferon alpha 2b
- Where
- Bangladesh
- Volunteers
- 160 people
- Sponsor
- Clinical Research Organization, Dhaka, Bangladesh
Hepatitis B, Chronic
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides
Both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are potent antiviral agents for hepatitis B virus (HBV) and recommended by the American Association for the Study of Liver Disease (AASLD) as well as the…
- Trial name
- NCT04201808
- Testing
- Tenofovir Alafenamide 25 MG
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- New Discovery LLC
Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
This study is a Phase Ib, multicenter randomized, double-blind, dose-escalation, placebo-controlled trial designed to evaluate the safety, tolerability, PK, and PD profiles of multiple-dose ACT500 in participants with metabolic…
- Trial name
- NCT07589400
- Testing
- ACT500 Tablets
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Acute-on-Chronic Liver Failure, Hepatitis B, Chronic
Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-Chronic
HBV-related acute-on-chronic liver failure (HBV-ACLF) deteriorates rapidly with a high short-term mortality. Early identification and accurate prognostic prediction was critical to improve survival rate.
- Trial name
- NCT03977857
- Where
- China
- Volunteers
- 486 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatitis B, Chronic, Mother to Child Transmission
Mother-to-child Transmission of HBV in China
In order to evaluate the feasibility of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030, a multi-center, prospective cohorts study was conducted to investigate MTCT of HBV in China.
- Trial name
- NCT05172453
- Testing
- comprehensive management algorithm for preventing mother-to-child transmission of HBV
- Where
- 15 sites in China
- Volunteers
- 50,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B
Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation
This is a phase IIIb comparative study of entecavir 1.0 mg once daily (QD) vs. adefovir 10 mg QD in patients who have chronic hepatitis B infection and hepatic decompensation.
- Trial name
- NCT00065507
- Testing
- Entecavir (ETV), Adefovir (ADV)
- Where
- 61 sites in United States, Brazil and 15 more
- Volunteers
- 195 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment
The purpose of this study is to assess the incidence of participants who reach hepatitis B surface antigen (HBsAg) seroclearance after discontinuing nucleos(t)ide analog (NA) therapy in participants with HBsAg less than or equal…
- Trial name
- SALMONS (NCT05550519)
- Testing
- Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Hepatitis B, Chronic
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT. in chronic hepatitis B Patients.
- Trial name
- NCT02588937
- Testing
- EntecaBell ODT. 0.5mg, Baraclude Tab. 0.5mg
- Where
- 9 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Hepatitis B
Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B
Chronic Hepatitis B is the most common cause of chronic viral liver disease worldwide afflicting 350 million persons, leading to significant morbidity and mortality due to liver disease and HCC in 20-40% of infected persons.
- Trial name
- DUAL (NCT02774837)
- Testing
- Tenofovir disoproxil, Telbivudine
- Where
- Singapore
- Volunteers
- 146 people
- Sponsor
- Seng Gee Lim
Hepatitis B, Chronic
The Clinical Cure Project of Chronic Hepatitis B in China
Chronic hepatitis B is a global public health problem, with nearly 700,000 deaths each year because of hepatitis B-related diseases.
- Trial name
- NCT04035837
- Testing
- pegylated interferon-alfa
- Where
- China
- Volunteers
- 30,000 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B
Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects
The purpose of this study is to evaluate the efficacy of Oxymatrine plus Lamivudine Combination Therapy and whether it could lower the incidence of Lamivudine long-term resistance compared to Lamivudine Monotherapy.
- Trial name
- NCT02202473
- Testing
- Lamivudine, Lamivudine+Oxymatrine Capsules
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Southeast University, China
Chronic Hepatitis B, Chronic Hepatitis D
Lamivudine for Chronic Hepatitis B
Chronic hepatitis B is a disease of the liver caused by the hepatitis B virus. It affects nearly 1 million Americans. Approximately 25% of patients with chronic hepatitis B will develop liver cirrhosis and 5% of patients will…
- Conditions
- Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
- Trial name
- NCT00001457
- Testing
- Lamivudine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b
Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104
The goal of this clinical trial is to test ISA104 in patients with chronic hepatitis B. The main question[s] it aims to answer are: How safe is ISA104? Does ISA104 induce immunity against hepatitis B virus? Different doses of the…
- Trial name
- HEB-PEP (NCT05841095)
- Testing
- ISA104
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Erasmus Medical Center
Chronic Hepatitis B
An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B
This study is an open-label, 2-Part (Single Ascending Dose [Part 1] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB).
- Trial name
- NCT06745973
- Testing
- EPI-003
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Epigenic Therapeutics, Inc
Hepatitis B, Chronic, Hepatitis C, Chronic
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
The investigators' pilot study indicates that hepatitis C virus (HCV)- and hepatitis B virus (HBV)-coinfected patients with predominantly active hepatitis C and those with predominantly active hepatitis B may need different…
- Trial name
- NCT00154869
- Testing
- Peginterferon Alfa-2a plus Ribavirin
- Where
- Taiwan
- Volunteers
- 320 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Chronic (CHB)
Study of AHB-171 in Chronic Hepatitis B Participants
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated…
- Trial name
- NCT07630727
- Testing
- AHB-171 Injection
- Where
- 10 sites in China
- Volunteers
- 138 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Hepatitis B
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB)…
- Trial name
- NCT03615066
- Testing
- Selgantolimod, TAF
- Where
- 10 sites in Canada, South Korea and 1 more
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Patients who have completed 3 years follow-up of the past Beijing Science and Technology Commission Research will receive another 7-years anti-viral therapy.
- Trial name
- NCT03366571
- Testing
- Nucleos(t)ide Analogues
- Where
- 4 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital